EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TAGETING IMMUNOTHERAPY

Journal Title: Universal Journal of Pharmaceutical Research - Year 2018, Vol 3, Issue 2

Abstract

EpCAM is a cell adhesion molecule. Its structure, its expression and the oncogenic potential, and its signaling network and target therapy were in concise reviewed. In recent advances,in addition to PI3K/akt and Raf/MAPK pathway involving in cell survival,anti-apoptosis and proliferation,and malignant initiation and progression(see figure by Zhu,1986-91), three distinct pathway are illustrated: EpCAM/E-cadherin-catenin-actin cytoskeleton, EpCAM/ wint-catenin signaling and its major EpCAM/ nuclear signaling presented by Maetzel D in 2009 and Munz M in 2004. Moreover, more accumulated data are needed in detail mechanism. The data may provide its cancer biology and clinical targeting therapy benefits.

Authors and Affiliations

George Zhu

Keywords

Related Articles

DEVELOPMENT AND EVALUATION OF ALBENDAZOLE MICROCAPSULE FOR COLONIC DRUG DELIVERY SYSTEM

At present scenario colon specific drug delivery has gained increased importance. Colon drug delivery system not only used for the treatment of local diseases, associated with the colon but also it is a potential site f...

FORMULATION AND EVALUATION OF METOCLOPRAMIDE HCL RECTAL SUPPOSITORIES

Metoclopramide hydrochloride is a dopamine receptor antagonist, used mostly for stomach and esophageal problems as it is a prokinetic agent. The aim of the present study was to design and evaluate the suppositories of Me...

PREVALENCE OF DYSLIPIDEMIA AND ITS ASSOCIATION WITH DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SULAIMANI GOVERNORATE

Rheumatoid arthritis is a systemic inflammatory disease characterized by chronic and erosive polyarthritis it is the most common inflammatory arthritis, affecting from 0.5-1% of the general population. Dyslipidemia is...

RISK FACTORS OF PERIODONTAL DISEASES AMONG YEMENI YOUNG DENTAL PATIENTS

Periodontal diseasesare chronic infectious diseases that lead to the inflammation of specialized tissues that surround and support the teeth. Many risk factors and risk indicators, associated with increased risk of perio...

DEVELOPMENT AND EVALUATION OF NANOEMULSION FORMULATIONS FOR IMPROVED ORAL DELIVERY OF CARVEDILOL

The aim of the present investigation was to develop, optimize and evaluate nanoemulsion system of carvedilol to improve its solubility, and oral bioavailability. Carvedilol is a non-selective beta blocker used in the tr...

Download PDF file
  • EP ID EP36458
  • DOI https://doi.org/10.22270/ujpr.v3i2.140
  • Views 328
  • Downloads 0

How To Cite

George Zhu (2018). EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TAGETING IMMUNOTHERAPY. Universal Journal of Pharmaceutical Research, 3(2), -. https://europub.co.uk/articles/-A-36458